Overview

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.
Phase:
Phase 2
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Collaborator:
Medpace, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Ezetimibe